Company: VERA
Filing Date: 2025-12-10
Form Type: 424B5
Source: 0001193125-25-314244
Chunk: 4

Company: Vera Therapeutics, Inc.
Filing Date: 2025-12-10
Form: 424B5
Chunk 4
---
 IgAN. In the Phase 2 PIONEER clinical trial, we are evaluating atacicept in expanded IgAN populations, as well as patients with anti-PLA2R positive primary membranous
nephropathy, or pMN, and anti-nephrin positive focal segmental glomerulosclerosis, or FSGS, and minimal change disease, or MCD. Potential other future indications include several rheumatologic diseases such as systemic lupus erythematosus and
Sjogren’s disease, and hematologic diseases, including idiopathic thrombocytopenic purpura and autoimmune hemolytic anemia. We also hold

S-1

exclusive rights to MAU868, a potentially first-in-class monoclonal antibody to treat reactivated BK virus, or BKV,
infections for which we completed a Phase 2 clinical trial in 2022, and in January 2025, we acquired exclusive rights to VT-109, a novel next-generation dual BAFF/APRIL inhibitor currently in preclinical
development. We believe that our current pipeline programs leverage the deep expertise of our team and have strong potential commercial synergies. We hold global developmental and commercial rights to all of our pipeline molecules.

Corporate information

We were initially incorporated in Delaware in May 2016
under the name CDF Therapeutics, Inc. In October 2017, we changed our name to Trucode Gene Repair, Inc., and in April 2020, we changed our name to Vera Therapeutics, Inc. Our principal executive offices are located at 2000 Sierra Point Parkway,
Suite 1200, Brisbane, California 94005, and our telephone number is (650) 770-0077. Our website address is www.veratx.com. Information contained in, or accessible through, our website is not a part of this
prospectus supplement, and the inclusion of our website address in this prospectus supplement is only an inactive textual reference.

We use the VERA THERAPEUTICS
word mark, Vera Therapeutics logo and other marks as trademarks in the United States and other countries. This prospectus supplement contains references to our trademarks and service marks and to those belonging to other entities. Solely for
convenience, trademarks and trade names referred to in this prospectus supplement, including logos, artwork and other visual displays, may appear without the or TM symbols, but such
references are not intended to indicate in any way that we